DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ctfx9t/idiopathic) has announced the addition of the "Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- AlphaMab Co., Ltd
- Biocon Limited
- Epirus Biopharmaceuticals, Inc.
- Genor BioPharma Co., Ltd.
- Mabion SA
- Oncodesign SA
- Panacea Biotec Limited
- Pfizer Inc.
- Sandoz International GmbH
- Swedish Orphan Biovitrum AB
- UCB S.A.
For more information visit http://www.researchandmarkets.com/research/ctfx9t/idiopathic